How participants in clinical studies enable medical progress

The heroes behind medicine: how participants in clinical studies enable medical progress

Drug discovery Boehringer Ingelheim

Every day, scientists at Boehringer Ingelheim embark on a journey. It is a journey that can take up to 15 years and requires significant investment. Only a tiny proportion of these journeys are successful.

Pioneering New Medicines Through External Innovation

On 22 November 2024 Boehringer Ingelheim hosted the event “Unleashing Innovation at Boehringer Ingelheim: Pioneering New Medicines Through External Innovation” at the Institute of Molecular Pathology (IMP)

Turning Point for Immunotherapy: Monocytes Strengthen T Cells

Immunotherapy boosts the immune system to fight cancer, but some tumors adapt and become resistant. The tumor’s microenvironment plays a complex role, sometimes blocking and sometimes aiding immune responses.

Unlocking the ‘dark genome’ for cancer immunotherapy

Our scientists are driving the discovery of unexplored cancer antigens from the ‘dark genome’ to develop novel cancer immunotherapies.

Partnering in Oncology AH JANUARY 2025 CORP

Provides a summary of Boehringer Ingelheim's animal health partnering interests in Oncology.

Partnering in Immunology & Inflammation AH JANUARY 2025 CORP

Summary of Boehringer Ingelheim Animal Health partnering interests in Immunology & Inflammation.